l*******2
发帖数: 1 | 1 季博士要采取行动了
https://www.globenewswire.com/news-release/2020/08/12/2077555/0/en/Sorrento-
to-Take-Action-Against-Hindenburg-Research-for-Statements-Believed-Intended-
to-Manipulate-Stock-Price.html
Sorrento to Take Action Against Hindenburg Research for Statements Believed
Intended to Manipulate Stock Price
August 12, 2020 19:51 ET | Source: Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (
NASDAQ: SRNE, "Sorrento") announced today that it believes it has uncovered
fraudulent attempts to manipulate the Company’s stock.
On August 11, 2020, it was reported that an organization calling itself “
Hindenburg Research” published claims regrading one of Sorrento’s COVID-19
diagnostic products. The report is believed to include false and/or
misleading statements for the sole apparent purpose of negatively
manipulating the company’s stock price.
Sorrento will collaborate with law enforcement and regulators to ensure that
any criminal activity is investigated and rectified. Sorrento, through its
legal counsel, Paul Hastings LLP, has demanded that the organization cease
and desist from illegal and wrongful activity and retract false and/or
misleading statements. Sorrento is also considering legal action.
Sorrento Therapeutics remains focused on developing a portfolio of COVID-19
solutions that spans diagnostics, prevention, early intervention and rescue
therapies, including its rapid on-site detection test for SARS-CoV-2 Virus
in saliva.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company
developing new therapies to treat cancers. Sorrento's multimodal,
multipronged approach to fighting cancer is made possible by its extensive
immuno-oncology platforms, including key assets such as fully human
antibodies ("G-MAB™ library"), clinical stage immuno-cellular
therapies ("CAR-T", "DAR-T™"), antibody-drug conjugates ("ADCs"), and
clinical stage oncolytic virus ("Seprehvir™", "Seprehvec™").
Sorrento is also developing potential antiviral therapies and vaccines
against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB&
#8482;, COVI-GUARD™, COVI-SHIELD™ and T-VIVA-19™; and
diagnostic test solutions, including COVI-TRACK™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also
demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-
opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido&#
174; (lidocaine topical system) 1.8% for the treatment of post-herpetic
neuralgia. RTX is completing a phase IB trial for intractable pain
associated with cancer and a phase 1B trial in osteoarthritis patients.
ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any presentation
or meeting contain forward-looking statements related to Sorrento
Therapeutics, Inc., under the safe harbor provisions of Section 21E of the
Private Securities Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially from
those projected. Forward-looking statements include statements regarding
Sorrento’s technologies, including COVI-TRACE™. Risks and
uncertainties that could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements, include,
but are not limited to: risks related to Sorrento’s technologies and other
risks that are described in Sorrento's most recent periodic reports filed
with the Securities and Exchange Commission, including Sorrento's Annual
Report on Form 10-K for the year ended December 31, 2019, and subsequent
Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission, including the risk factors set forth in those filings. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release and we undertake
no obligation to update any forward-looking statement in this press release
except as required by law.
Media and Investor Relations
Alexis Nahama, SVP Corporate Development
Telephone: 1.858.203.4120
Email: [email protected]
Sorrento® and the Sorrento logo are registered trademarks of Sorrento
Therapeutics, Inc.
ZTlido® and G-MAB™ are trademarks owned by Scilex Pharmaceuticals
Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics Limited, a
wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of
companies owned by Sorrento Therapeutics, Inc.
All other trademarks are the property of their respective owners.
© 2020 Sorrento Therapeutics, Inc. All Rights Reserved. |
|
